Dr. Deborah F. MacFarlane, MD

Dr. MacFarlane practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. MacFarlane's NPI, 1700820859, was assigned on June 16, 2006. Dr. MacFarlane holds Texas license L7465.

Dr. MacFarlane's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. MacFarlane's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Houston Dermatology Specialists. Dmand AI also links Dr. MacFarlane to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. MacFarlane practices, 2 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. MacFarlane's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. MacFarlane is licensed in Texas.

CMS data shows 2,189 Medicare services from Dr. MacFarlane across 26 procedure codes in 2024, for 443 Medicare patients. Medicare paid $227,450 for them. Every service was in an office.

CMS counts 443 Medicare patients who saw Dr. MacFarlane in 2024. The largest group is 75 to 84, with 193 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.60, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. MacFarlane's median patient age at 75, with 39% women.

In 2024, Dr. MacFarlane wrote 225 Medicare Part D claims for 162 patients. 100% of them were for generic drugs. CMS names the drug for 205 of them, across 4 drugs with 11 or more claims each, at $2,744 in total drug cost. In 2023, CMS named 224 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. MacFarlane for performance year 2024, reported as part of a group. Dr. MacFarlane accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 29 procedures of melanoma (skin cancer) excision by Dr. MacFarlane, more than 80% of the clinicians it reports for that procedure.

Dmand AI links 35 papers to Dr. MacFarlane, published from 2012 to 2025. 2015 was the busiest year, with 4. The most frequent topics are Skin Neoplasms, Carcinoma, Squamous Cell and Carcinoma, Basal Cell. Dr. MacFarlane has published most often in J Am Acad Dermatol. Dr. MacFarlane's most frequent co-authors are Philip R. Cohen, MD, Timothy James Hansen, MD and Ikue Shimizu, MD.

CMS Open Payments shows 2 general payments to Dr. MacFarlane from 2 drug and device companies from 2019 to 2024. Food and beverage make up the largest share, 100% of the total. UCB, Inc. paid the most, $46.